# Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

> **NCT04655092** · PHASE3 · RECRUITING · sponsor: **PharmaEssentia Japan K.K.** · enrollment: 67 (estimated)

## Conditions studied

- Polycythemia Vera (PV)

## Interventions

- **BIOLOGICAL:** P1101 (Ropeginterferon alfa-2b)

## Key facts

- **NCT ID:** NCT04655092
- **Lead sponsor:** PharmaEssentia Japan K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-19
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04655092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04655092, "Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04655092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*